This Article Full Text Full Text (PDF) Supplemental Data Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hsiung, H. M. Articles by Yan, L. Z. Search for Related Content PubMed PubMed Citation Articles by Hsiung, H. M. Articles by Yan, L. Z.

A Novel and Selective ß-Melanocyte-Stimulating Hormone-Derived Peptide Agonist for Melanocortin 4 Receptor Potently Decreased Food Intake and Body Weight Gain in Diet-Induced Obese Rats

Divisions of Endocrine Research (H.M.H., J.H., X.Z., D.P.S., M.L.H.), Bio-therapeutics Discovery Research (D.L.S., D.D.Y., J.P.M., L.Z., L.Z.Y.), Discovery Chemistry and Research Technology (H.M.), and Lead Optimization Biology (S.H.), Eli Lilly & Co., Indianapolis, Indiana 46285

Address all correspondence and requests for reprints to: Hansen M. Hsiung, Ph.D., Obesity Drug Hunting Team, DC0424 Lilly Corporate Center, Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, Indiana 46285. E-mail: hansenhsiung5{at}yahoo.com.

MSH has generally been accepted as the endogenous ligand for melanocortin 4 receptor (MC4R), which plays a major role in energy homeostasis. Targeting MC4R to develop antiobesity agents, many investigators have performed a structure-activity relationship (SAR) studies based on MSH structure. In this report, we performed a SAR study using human ßMSH (5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 ) (DEGPYRMEHFRWGSPPKD, peptide 1) as a lead sequence to develop potent and selective agonists for MC4R and MC3R. The SAR study was begun with a truncation of N terminus of ßMSH (5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 ) together with acetylation of the N terminus and amidation of the C terminus of the peptide. Introduction of a cyclic disulfide constrain and replacement of L-Phe with D-Phe afforded a super potent agonist (peptide 5). Furthermore truncation at the C terminus generated a small and potent MC4R and MC3R agonist (Ac-YRcyclo[CEHdFRWC]amide, peptide 6), which exhibited no MC5R and greatly reduced MC1R activity. Molecular modeling of Ac-YRcyclo[CEHdFRWC]amide (peptide 6) revealed that Arg2 in the peptide formed a salt bridge with Glu4. Subcutaneous or intracerebroventricular administration of peptide 6 in rats showed potent in vivo efficacy as evidenced by its effects in reducing energy balance, increasing fat use, and decreasing weight gain in both acute and chronic rat metabolic studies. Furthermore, the antiobesity effect by peptide 6 was manifested only in wild-type but not MC4R-deficient mice, indicating that antiobesity effects of the peptide were attributed largely through MC4R but not MC3R agonist activity of the peptide.

This article has been cited by other articles:

				H. Shimizu, S. Oh-I, K. Hashimoto, M. Nakata, S. Yamamoto, N. Yoshida, H. Eguchi, I. Kato, K. Inoue, T. Satoh, et al. Peripheral Administration of Nesfatin-1 Reduces Food Intake in Mice: The Leptin-Independent Mechanism Endocrinology, February 1, 2009; 150(2): 662 - 671. [Abstract] [Full Text] [PDF]

				D. D. Lam, M. J. Przydzial, S. H. Ridley, G. S. H. Yeo, J. J. Rochford, S. O'Rahilly, and L. K. Heisler Serotonin 5-HT2C Receptor Agonist Promotes Hypophagia via Downstream Activation of Melanocortin 4 Receptors Endocrinology, March 1, 2008; 149(3): 1323 - 1328. [Abstract] [Full Text] [PDF]

				I. S. Farooqi and S. O'Rahilly Genetics of Obesity in Humans Endocr. Rev., December 1, 2006; 27(7): 710 - 718. [Abstract] [Full Text] [PDF]